What does Bio-View Ltd do?

Bio-View Ltd (BIOV.TA) operates in the Medical - Devices industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is BIOV.TA's market cap?

Bio-View Ltd (BIOV.TA) has a market capitalization of approximately $1.16 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.

Does BIOV.TA pay a dividend?

Yes — Bio-View Ltd (BIOV.TA) has a dividend payment history. The most recent payment, frequency, and full history are on the Dividend tab.

Is BIOV.TA profitable?

Bio-View Ltd (BIOV.TA) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

BIOV.TA

Bio-View Ltd

TLV·Medical, Devices · Healthcare

ILA 83.30ILA 2.00+2.46%

Market capILA 1.16B·Aug 26 7:15 AM UTC

Price Chart

ILA 83.30+ILA 2.00 (+2.46%)today

−99.97%CAGR −80.66%

Select date range

FromTo

Mar 13, 2006Aug 26, 2021 → Aug 26, 2026· 5.0 yrsAug 26, 2026

Key Metrics

DividendDividend Tab

Dividend Yield (FWD)0.00%

Annual Dividend (FWD)ILA 0.00

Dividend Growth (5Y)—

Dividend Safety—

Payout Ratio—

FCF Payout Ratio—

Most Recent DividendILA 200.00

Ex-Dividend DateMar 22

Payment DateApr 6

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings DateDec 9

Last Report DateDec 9

Reported vs Estimate−ILA 0.19

Earnings Surprise—

FinancialsFinancials Tab

Revenue₪19.93M

Net Income−₪15.33M

Net Margin−76.9%

Operating Cash Flow−₪3.06M

Capital Expenditures₪53.00K

Free Cash Flow−₪3.11M

Return on Equity−162.8%

Return on Invested Capital−11.3%

Net Cash₪4.43M

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for BIOV.TA and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how BIOV.TA's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for BIOV.TA and 80,000+ other tickers.

About Bio-View Ltd

Bio-View Ltd, founded in 2000 and headquartered in Rehovot, Israel, is a developer, manufacturer, and global distributor of advanced automated cell imaging and analysis systems. These sophisticated solutions are utilized by clinical and research laboratories worldwide, specifically in the fields of cytology, cytogenetics, and pathology. The company's extensive product lineup includes: Accord: A semi-automated fluorescent imaging and analysis workbench microscope station. Accord Plus: An automatic fluorescent imaging system capable of real-time scanning, analysis, and sorting of diverse FISH…

CEO: Daniel Klain
Sector: Healthcare
Industry: Medical - Devices
Exchange: TLV
Employees: 30
Website: www.bioview.com

Peers

Peers Tab

EMTC-M.TA

Elbit Medical Technologies Ltd

Cap

ILA 2.0B

BOLT.TA

BioLight Life Sciences Ltd.

Cap

ILA 2.5B

MRHL.TA

Merchavia Holdings and Investments Ltd.

Cap

ILA 3.3B

Latest News

News Tab

No recent news available.

Frequently Asked Questions About BIOV.TA

What does Bio-View Ltd do?: Bio-View Ltd (BIOV.TA) operates in the Medical - Devices industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is BIOV.TA's market cap?: Bio-View Ltd (BIOV.TA) has a market capitalization of approximately $1.16 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.
Does BIOV.TA pay a dividend?: Yes — Bio-View Ltd (BIOV.TA) has a dividend payment history. The most recent payment, frequency, and full history are on the Dividend tab.
Is BIOV.TA profitable?: Bio-View Ltd (BIOV.TA) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.